Literature DB >> 26886504

The Universal 3D3 Antibody of Human PODXL Is Pluripotent Cytotoxic, and Identifies a Residual Population After Extended Differentiation of Pluripotent Stem Cells.

Lei Kang1,2, Chunping Yao1,2,3, Alireza Khodadadi-Jamayran1,2, Weihua Xu1,2,4, Ruowen Zhang1,2, Nilam Sanjib Banerjee2, Chia-Wei Chang1,2, Louise T Chow2, Tim Townes1,2, Kejin Hu1,2.   

Abstract

Podocalyxin-like protein (PODXL) is a member of CD34 family proteins. It is the protein that carries many post-translational epitopes responsible for various pluripotent surface markers including TRA-1-60, TRA-1-81, GCTM2, GP200, and mAb84. However, PODXL has not attracted the attention of stem cell biologists. Here, we report several features of PODXL mRNA and protein in pluripotent stem cells. Similar to the modification-dependent pluripotent epitopes, PODXL transcripts and carrier protein are also features of pluripotency. PODXL is highly expressed in early human embryos from oocytes up to four-cell stages. During reprogramming of human cells to pluripotency, in contrast to TRA-1-60 and TRA-1-81, PODXL is activated by KLF4 at a very early time of reprogramming. Although TRA-1-60 and TRA-1-81 are completely lost upon differentiation, a residual PODXL(+) population exists even after extended differentiation and they were identified by the universal human PODXL epitope 3D3. Unlike TRA-1-60 and TRA-1-81 epitopes that are unique to primate pluripotent stem cells (PSCs), PODXL carrier protein can be used as a murine surface marker. Most importantly, antibody to 3D3 epitope causes massive necrosis and apoptosis of human PSCs (hPSCs). We suggest that 3D3 antibody could be employed to eliminate the tumorigenic pluripotent cells in hPSC-derived cells for cell transplantation.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26886504      PMCID: PMC4817563          DOI: 10.1089/scd.2015.0321

Source DB:  PubMed          Journal:  Stem Cells Dev        ISSN: 1547-3287            Impact factor:   3.272


  67 in total

1.  Assessing self-renewal and differentiation in human embryonic stem cell lines.

Authors:  Jingli Cai; Jia Chen; Ying Liu; Takumi Miura; Yongquan Luo; Jeanne F Loring; William J Freed; Mahendra S Rao; Xianmin Zeng
Journal:  Stem Cells       Date:  2005-11-17       Impact factor: 6.277

2.  Core transcriptional regulatory circuitry in human embryonic stem cells.

Authors:  Laurie A Boyer; Tong Ihn Lee; Megan F Cole; Sarah E Johnstone; Stuart S Levine; Jacob P Zucker; Matthew G Guenther; Roshan M Kumar; Heather L Murray; Richard G Jenner; David K Gifford; Douglas A Melton; Rudolf Jaenisch; Richard A Young
Journal:  Cell       Date:  2005-09-23       Impact factor: 41.582

Review 3.  Vectorology and factor delivery in induced pluripotent stem cell reprogramming.

Authors:  Kejin Hu
Journal:  Stem Cells Dev       Date:  2014-04-16       Impact factor: 3.272

4.  Teratoma formation leads to failure of treatment for type I diabetes using embryonic stem cell-derived insulin-producing cells.

Authors:  Takahisa Fujikawa; Seh-Hoon Oh; Liya Pi; Heather M Hatch; Tom Shupe; Bryon E Petersen
Journal:  Am J Pathol       Date:  2005-06       Impact factor: 4.307

5.  Improved safety of hematopoietic transplantation with monkey embryonic stem cells in the allogeneic setting.

Authors:  Hiroaki Shibata; Naohide Ageyama; Yujiro Tanaka; Yukiko Kishi; Kyoko Sasaki; Shinichiro Nakamura; Shin-ichi Muramatsu; Satoshi Hayashi; Yoshihiro Kitano; Keiji Terao; Yutaka Hanazono
Journal:  Stem Cells       Date:  2006-02-02       Impact factor: 6.277

6.  Expression of podocalyxin enhances the adherence, migration, and intercellular communication of cells.

Authors:  Susana Larrucea; Nora Butta; Elena G Arias-Salgado; Sonia Alonso-Martin; Matilde S Ayuso; Roberto Parrilla
Journal:  Exp Cell Res       Date:  2008-03-20       Impact factor: 3.905

7.  Efficient human iPS cell derivation by a non-integrating plasmid from blood cells with unique epigenetic and gene expression signatures.

Authors:  Bin-Kuan Chou; Prashant Mali; Xiaosong Huang; Zhaohui Ye; Sarah N Dowey; Linda Ms Resar; Chunlin Zou; Y Alex Zhang; Jay Tong; Linzhao Cheng
Journal:  Cell Res       Date:  2011-01-18       Impact factor: 25.617

8.  HTSeq--a Python framework to work with high-throughput sequencing data.

Authors:  Simon Anders; Paul Theodor Pyl; Wolfgang Huber
Journal:  Bioinformatics       Date:  2014-09-25       Impact factor: 6.937

9.  Genome-wide DNA methylation map of human neutrophils reveals widespread inter-individual epigenetic variation.

Authors:  Aniruddha Chatterjee; Peter A Stockwell; Euan J Rodger; Elizabeth J Duncan; Matthew F Parry; Robert J Weeks; Ian M Morison
Journal:  Sci Rep       Date:  2015-11-27       Impact factor: 4.379

10.  A new class of pluripotent stem cell cytotoxic small molecules.

Authors:  Mark Richards; Chee Wee Phoon; Gwendoline Tze Wei Goh; Eng Khuan Seng; Xu Ming Guo; Cherine Mei Fong Tan; Woon-Khiong Chan; Joel Mun Kin Lee
Journal:  PLoS One       Date:  2014-03-19       Impact factor: 3.240

View more
  10 in total

1.  Targeting a Tumor-Specific Epitope on Podocalyxin Increases Survival in Human Tumor Preclinical Models.

Authors:  Diana Canals Hernaez; Michael R Hughes; Yicong Li; Ilaria Mainero Rocca; Pamela Dean; Julyanne Brassard; Erin M Bell; Ismael Samudio; Anne-Marie Mes-Masson; Yoshiki Narimatsu; Henrik Clausen; Ola Blixt; Calvin D Roskelley; Kelly M McNagny
Journal:  Front Oncol       Date:  2022-05-04       Impact factor: 5.738

2.  Anti-podocalyxin antibody exerts antitumor effects via antibody-dependent cellular cytotoxicity in mouse xenograft models of oral squamous cell carcinoma.

Authors:  Shunsuke Itai; Tomokazu Ohishi; Mika K Kaneko; Shinji Yamada; Shinji Abe; Takuro Nakamura; Miyuki Yanaka; Yao-Wen Chang; Shun-Ichi Ohba; Yasuhiko Nishioka; Manabu Kawada; Hiroyuki Harada; Yukinari Kato
Journal:  Oncotarget       Date:  2018-04-27

3.  Determination of critical epitope of PcMab-47 against human podocalyxin.

Authors:  Shunsuke Itai; Shinji Yamada; Mika K Kaneko; Yukinari Kato
Journal:  Biochem Biophys Rep       Date:  2018-04-24

4.  Profiling and quantification of pluripotency reprogramming reveal that WNT pathways and cell morphology have to be reprogramed extensively.

Authors:  Kejin Hu; Lara Ianov; David Crossman
Journal:  Heliyon       Date:  2020-05-27

5.  Human transcription factors responsive to initial reprogramming predominantly undergo legitimate reprogramming during fibroblast conversion to iPSCs.

Authors:  Ricardo R Cevallos; Yvonne J K Edwards; John M Parant; Bradley K Yoder; Kejin Hu
Journal:  Sci Rep       Date:  2020-11-12       Impact factor: 4.379

6.  Salicylic diamines selectively eliminate residual undifferentiated cells from pluripotent stem cell-derived cardiomyocyte preparations.

Authors:  Karsten Burkert; Hadiseh Taheri; Sarkawt Hamad; Matteo Oliverio; Gabriel Peinkofer; Jan-Wilhelm Kornfeld; Wacharee Harnying; Kurt Pfannkuche; Jürgen Hescheler; Albrecht Berkessel; Tomo Šarić
Journal:  Sci Rep       Date:  2021-01-27       Impact factor: 4.379

7.  Become Competent within One Day in Generating Boxplots and Violin Plots for a Novice without Prior R Experience.

Authors:  Kejin Hu
Journal:  Methods Protoc       Date:  2020-09-23

8.  Liquid condensation of reprogramming factor KLF4 with DNA provides a mechanism for chromatin organization.

Authors:  Rajesh Sharma; Kyoung-Jae Choi; My Diem Quan; Sonum Sharma; Banumathi Sankaran; Hyekyung Park; Anel LaGrone; Jean J Kim; Kevin R MacKenzie; Allan Chris M Ferreon; Choel Kim; Josephine C Ferreon
Journal:  Nat Commun       Date:  2021-09-22       Impact factor: 14.919

9.  A PIANO (Proper, Insufficient, Aberrant, and NO Reprogramming) Response to the Yamanaka Factors in the Initial Stages of Human iPSC Reprogramming.

Authors:  Kejin Hu
Journal:  Int J Mol Sci       Date:  2020-05-02       Impact factor: 5.923

10.  Identification of LEA, a podocalyxin-like glycoprotein, as a predictor for the progression of colorectal cancer.

Authors:  Dezheng Yuan; Hang Chen; Shuo Wang; Furong Liu; Yajie Cheng; Jin Fang
Journal:  Cancer Med       Date:  2018-09-12       Impact factor: 4.452

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.